Literature DB >> 15487938

Herpes vector-mediated gene transfer in treatment of diseases of the nervous system.

Joseph C Glorioso1, David J Fink.   

Abstract

Vectors constructed from recombinant herpes simplex virus (HSV) have special utility for gene transfer to the nervous system. Nonreplicating vectors created by deletion of essential immediate early genes can be propagated to high titers on complementing cell lines that provide the missing gene product(s) in trans. Direct inoculation of these vectors into neural parenchyma is effective in rodent models of brain tumor, Parkinson disease, spinal cord injury, and spinal root trauma. Subcutaneous inoculation of the HSV vectors can be used to transduce neurons of the dorsal root ganglion to provide a therapeutic effect in models of polyneuropathy and chronic regional pain. In human trials, direct injection of replication-competent HSV into brain tumors has proven safe. Human trials of nonreplicating HSV gene transfer by direct inoculation for treatment of glioblastoma and HSV gene transfer by subcutaneous inoculation for the treatment of chronic intractable pain should commence soon.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15487938     DOI: 10.1146/annurev.micro.58.030603.123709

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  31 in total

1.  Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury.

Authors:  Darryl Lau; Steven E Harte; Thomas J Morrow; Shiyong Wang; Marina Mata; David J Fink
Journal:  Neurorehabil Neural Repair       Date:  2012-05-15       Impact factor: 3.919

Review 2.  Viral vector-based gene transfer for treatment of chronic pain.

Authors:  Shuanglin Hao; Marina Mata; David J Fink
Journal:  Int Anesthesiol Clin       Date:  2007

3.  Gene delivery to the nervous system.

Authors:  Manfred Schubert; Xandra Breakefield; Howard Federoff; Robert M Frederickson; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2008-04       Impact factor: 11.454

Review 4.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

5.  Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons.

Authors:  Munmun Chattopadhyay; Marina Mata; David J Fink
Journal:  Eur J Pain       Date:  2011-04-12       Impact factor: 3.931

6.  Modulating pain in the periphery: gene-based therapies to enhance peripheral opioid analgesia: Bonica lecture, ASRA 2010.

Authors:  Srinivasa N Raja
Journal:  Reg Anesth Pain Med       Date:  2012 Mar-Apr       Impact factor: 6.288

Review 7.  HSV gene transfer in the treatment of chronic pain.

Authors:  David J Fink; Marina Mata
Journal:  Sheng Li Xue Bao       Date:  2008-10-25

8.  Extreme susceptibility of African naked mole rats (Heterocephalus glaber) to experimental infection with herpes simplex virus type 1.

Authors:  James Artwohl; Susan Ball-Kell; Tibor Valyi-Nagy; Steven P Wilson; Ying Lu; Thomas J Park
Journal:  Comp Med       Date:  2009-02       Impact factor: 0.982

Review 9.  Gene therapy for the treatment of diabetic neuropathy.

Authors:  Marina Mata; Munmun Chattopadhyay; David J Fink
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

10.  HSV-mediated gene transfer of C3 transferase inhibits Rho to promote axonal regeneration.

Authors:  Zhigang Zhou; Xiangmin Peng; Peipei Chiang; Jeeyong Kim; Xiankui Sun; David J Fink; Marina Mata
Journal:  Exp Neurol       Date:  2012-06-26       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.